ArticleCureus2026
Orthognathic Surgery Using 1-Desamino-8-D-Arginine Vasopressin (DDAVP) in a Patient With Von Willebrand Disease: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Von Willebrand disease (vWD) is a bleeding disorder with autosomal-dominant inheritance caused by quantitative and qualitative abnormalities in von Willebrand factor (vWF), which plays a role in primary hemostasis. In such cases, it is necessary to evaluate hemostatic function prior to surgery and take appropriate measures to manage bleeding. There are few reports on orthognathic surgery, which is a highly invasive procedure in the oral and maxillofacial regions, and all of them use blood products. We report a case of orthognathic surgery using 1-desamino-8-D-arginine vasopressin (DDAVP), a synthetic antidiuretic hormone, in a patient with vWD for jaw deformity. We report a case of orthognathic surgery using DDAVP, a synthetic antidiuretic hormone, in a patient with vWD for jaw deformity. A 26-year-old Japanese female visited another clinic with a chief complaint of mandibular prognathism and started preoperative orthodontic treatment for jaw deformity. Preoperative screening and examinations revealed prolonged APTT and decreased coagulation factor activity. The patient was referred to the hematology department at our hospital and diagnosed with type Ⅰ vWD (quantitative reduction in vWF). The patient was referred to our department for orthognathic surgery, and LeFort I osteotomy and bilateral sagittal split ramus osteotomy were planned to improve occlusion. The patient underwent a challenge test using intravenous injection of DDAVP in the hematology department to establish a response to DDAVP prior to surgery. As a result, an increase in vWD antigen levels and vWF activity was confirmed, and surgery was performed using DDAVP. There were no perioperative complications, and the patient's perioperative course was uneventful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.